Get a data.frame of projects, simulations and observed data
getSimulationsObsDataFromProjects(projectData)A data.frame with columns `Project`, `Simulation` and `ObservedData`
# Get the project data from a list of paths
snapshotPaths <- list(
"Raltegravir" = file.path(
"https://raw.githubusercontent.com",
"Open-Systems-Pharmacology",
"Raltegravir-Model",
"v1.2",
"Raltegravir-Model.json"
),
"Atazanavir" = file.path(
"https://raw.githubusercontent.com",
"Open-Systems-Pharmacology",
"Atazanavir-Model",
"v1.2",
"Atazanavir-Model.json"
)
)
projectData <- getProjectsFromList(snapshotPaths)
# Get the simulations Observed Data from the projects
getSimulationsObsDataFromProjects(projectData)
#> Project Simulation
#> 1 Raltegravir Raltegravir 800 mg (lactose formulation)
#> 2 Raltegravir Raltegravir 10 mg (lactose formulation)
#> 3 Raltegravir Raltegravir 100 mg (lactose formulation)
#> 4 Raltegravir Raltegravir 1200 mg (lactose formulation)
#> 5 Raltegravir Raltegravir 1600 mg (lactose formulation)
#> 6 Raltegravir Raltegravir 200 mg (lactose formulation)
#> 7 Raltegravir Raltegravir 25 mg (lactose formulation)
#> 8 Raltegravir Raltegravir 50 mg (lactose formulation)
#> 9 Raltegravir Raltegravir 400mg chewable fasted
#> 10 Raltegravir Raltegravir 400mg filmcoated tablet
#> 11 Raltegravir Raltegravir 400mg filmcoated tablet
#> 12 Raltegravir Raltegravir 400mg filmcoated tablet
#> 13 Raltegravir Raltegravir 400mg (lactose formulation)
#> 14 Raltegravir Raltegravir 100 mg filmcoated tablet md
#> 15 Raltegravir Raltegravir 200 mg filmcoated tablet md
#> 16 Raltegravir Raltegravir 200 mg filmcoated tablet md
#> 17 Raltegravir Raltegravir 400 mg filmcoated tablet md
#> 18 Raltegravir Raltegravir 400mg (granules in suspension)
#> 19 Raltegravir Raltegravir 400mg chewable fed
#> 20 Atazanavir Acosta2007_300mg
#> 21 Atazanavir Agarwala2003_400mg
#> 22 Atazanavir Agarwala2005a_400mg
#> 23 Atazanavir Agarwala2005b_400mg
#> 24 Atazanavir Martin2008_400mg
#> 25 Atazanavir Zhu2011_400mg
#> 26 Atazanavir Zhu2011_400mg
#> 27 Atazanavir FDA-ClinPharmReview_AI424-014_400mg_YoungFemales
#> 28 Atazanavir FDA-ClinPharmReview_AI424-028_200mg
#> 29 Atazanavir FDA-ClinPharmReview_AI424-028_200mg
#> 30 Atazanavir FDA-ClinPharmReview_AI424-028_400mg
#> 31 Atazanavir FDA-ClinPharmReview_AI424-028_400mg
#> 32 Atazanavir FDA-ClinPharmReview_AI424-040_200mg
#> 33 Atazanavir FDA-ClinPharmReview_AI424-040_400mg
#> 34 Atazanavir FDA-ClinPharmReview_AI424-040_800mg
#> 35 Atazanavir FDA-ClinPharmReview_AI424-056_300mg
#> 36 Atazanavir FDA-ClinPharmReview_AI424-076_400mg
#> 37 Atazanavir FDA-ClinPharmReview_AI424-076_800mg
#> 38 Atazanavir Zhu2010_300mg_Atazanavir
#> 39 Atazanavir FDA-ClinPharmReview_AI424-004_400mg_TreatmentA
#> 40 Atazanavir FDA-ClinPharmReview_AI424-014_400mg_YoungMales
#> 41 Atazanavir FDA-ClinPharmReview_AI424-014_400mg_YoungMales
#> 42 Atazanavir FDA-ClinPharmReview_AI424-015_400mg_NormalSubjects
#> ObservedData
#> 1 Iwamoto 2008 - 800mg - Raltegravir - PO - 800 mg - Plasma - agg. (n=24)
#> 2 Iwamoto 2008 - 10mg - Raltegravir - PO - 10 mg - Plasma - agg. (n=24)
#> 3 Iwamoto 2008 - 100mg - Raltegravir - PO - 100 mg - Plasma - agg. (n=24)
#> 4 Iwamoto 2008 - 1200mg - Raltegravir - PO - 1200 mg - Plasma - agg. (n=24)
#> 5 Iwamoto 2008 - 1600mg - Raltegravir - PO - 1600 mg - Plasma - agg. (n=24)
#> 6 Iwamoto 2008 - 200mg - Raltegravir - PO - 200 mg - Plasma - agg. (n=24)
#> 7 Iwamoto 2008 - 25mg - Raltegravir - PO - 25 mg - Plasma - agg. (n=24)
#> 8 Iwamoto 2008 - 50mg - Raltegravir - PO - 50 mg - Plasma - agg. (n=24)
#> 9 Rhee 2014 - Chewable tablet fasted - Raltegravir - po - 400 mg - Plasma - agg. (n=12)
#> 10 Rhee 2014 - filmcoated tablet - Raltegravir - po - 400 mg - Plasma - agg. (n=12)
#> 11 Wenning 2009 - 400mg - Raltegravir - PO - 400 mg - Plasma - agg. (n=10)
#> 12 Iwamoto 2008 - 400mg FCT - Raltegravir - PO - 400 mg - Plasma - agg. (n=14)
#> 13 Iwamoto 2008 - 400mg - Raltegravir - PO - 400 mg - Plasma - agg. (n=24)
#> 14 Markowitz 2006 - 100mg FCT MD - Raltegravir - PO - 100 mg - Plasma - agg. (n=7)
#> 15 Markowitz 2006 - 200mg FCT MD - Raltegravir - PO - 200 mg - Plasma - agg. (n=7)
#> 16 Kassahun 2007 - 200mg FCT SD - Raltegravir - PO - 200 mg - Plasma - agg. (n=8)
#> 17 Markowitz 2006 - 400mg FCT MD - Raltegravir - PO - 400 mg - Plasma - agg. (n=6)
#> 18 Rhee 2014 - granules suspension - Raltegravir - po - 400 mg - Plasma - agg. (n=12)
#> 19 Rhee 2014 - Chewable tablet fed - Raltegravir - po - 400 mg - Plasma - agg. (n=12)
#> 20 Acosta 2007 - Period 1 - Atazanavir - PO - 300 mg - Plasma - agg. (n=10)
#> 21 Agarwala 2003 - Day 6 - Atazanavir - PO - 400 mg - Plasma - agg. (n=65)
#> 22 Agarwala 2005a - ATV 400 mg AM (N=15) - Atazanavir - PO - 400 mg - Plasma - agg. (n=15)
#> 23 Agarwala 2005b - ATV 400 mg (Treatment A) - Atazanavir - PO - 400 mg - Plasma - agg. (n=16)
#> 24 Martin 2008 - Atazanavir monotherapy (n = 24) - Atazanavir - PO - 400 mg - Plasma - agg. (n=24)
#> 25 Zhu 2011 - Treatment A: Atazanavir 400 mg QPM - Atazanavir - PO - 400 mg - Plasma - agg. (n=28)
#> 26 Zhu 2011 - Treatment B: Atazanavir 400 mg QAM - Atazanavir - PO - 400 mg - Plasma - agg. (n=28)
#> 27 ClinPharmReview, AI424-014, p. 77 - Young Females - Atazanavir - PO - 400 mg - Plasma - agg. (n=14)
#> 28 ClinPharmReview, AI424-028, p. 128 - A-Day 6 - Atazanavir - PO - 200 mg - Plasma - agg. (n=8)
#> 29 ClinPharmReview, AI424-028, p. 128 - B-Day 6 - Atazanavir - PO - 200 mg - Plasma - agg. (n=8)
#> 30 ClinPharmReview, AI424-028, p. 128 - C-Day 6 - Atazanavir - PO - 400 mg - Plasma - agg. (n=8)
#> 31 ClinPharmReview, AI424-028, p. 128 - D-Day 6 - Atazanavir - PO - 400 mg - Plasma - agg. (n=8)
#> 32 ClinPharmReview, AI424-040, p. 64 - 200 mg - Atazanavir - PO - 200 mg - Plasma - agg. (n=20)
#> 33 ClinPharmReview, AI424-040, p. 64 - 400 mg - Atazanavir - PO - 400 mg - Plasma - agg. (n=20)
#> 34 ClinPharmReview, AI424-040, p. 64 - 800 mg - Atazanavir - PO - 800 mg - Plasma - agg. (n=20)
#> 35 ClinPharmReview, AI424-056, p. 134 - Atazanavir without ritonavir, Day 10 - Atazanavir - PO - 300 mg - Plasma - agg. (n=30)
#> 36 ClinPharmReview, AI424-076, p. 178 - 400 mg - Atazanavir - PO - 400 mg - Plasma - agg. (n=65)
#> 37 ClinPharmReview, AI424-076, p. 178 - 800 mg - Atazanavir - PO - 800 mg - Plasma - agg. (n=66)
#> 38 Zhu 2010 - Atazanvir 300 mg twice daily - Atazanavir - PO - 300 mg - Plasma - agg. (n=22)
#> 39 ClinPharmReview, AI424-004, p. 94 - Treatment A - Atazanavir - PO - 400 mg - Plasma - agg. (n=32)
#> 40 ClinPharmReview, AI424-029, p. 47 - Urinary radioactivity - Atazanavir - PO - 400 - Urine - agg. (n=12)
#> 41 ClinPharmReview, AI424-014, p. 77 - Young Males - Atazanavir - PO - 400 mg - Plasma - agg. (n=15)
#> 42 ClinPharmReview, AI424-015, p. 81 - Normal subjects - Atazanavir - PO - 400 mg - Plasma - agg. (n=16)